Doug Kohrs appointed to Sequana Medical Board of Directors

Highly experienced US medtech leader brings more than 40 years’ experience

Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent Non-Executive Director of the Company. Mr. Kohrs is a highly experienced US executive with a track record of more than 40 years in the medical device industry.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...